US Patent Issued to BIONTECH CELL & GENE THERAPIES on April 7 for "Interleukin-2 receptor (IL2R) and interleukin-2 (IL2) variants for specific activation of immune effector cells" (German Inventors)

ALEXANDRIA, Va., April 7 -- United States Patent no. 12,595,292, issued on April 7, was assigned to BIONTECH CELL & GENE THERAPIES GMBH (Mainz, Germany).

"Interleukin-2 receptor (IL2R) and interleukin-2 (IL2) variants for specific activation of immune effector cells" was invented by Ugur Sahin (Mainz, Germany), Sina Fellermeier-Kopf (Mainz, Germany), Alexander Muik (Mainz, Germany) and Matthias Birtel (Mainz, Germany).

According to the abstract* released by the U.S. Patent & Trademark Office: "The invention relates to variants of the alpha subunit of interleukin-2 receptor (IL2R) and interleukin-2 (IL2). In one embodiment, the IL2 variants described herein have amino acid substitutions at the region of IL2 that contacts the alpha (Alpha) ...